Cilostazol

Cilostazol is a selective PDE3 inhibitor that inhibits platelet aggregation and causes vasodilation. It is used for the treatment of intermittent claudication in peripheral arterial disease and for prevention of secondary stroke. Mediocon Inc supplies pharmaceutical-grade Cilostazol meeting IP/BP/EP/USP standards.

Key Features

• Selective PDE3 inhibitor with antiplatelet activity
• IP/BP/EP/USP compliant, Assay 99.0% Min.
• Treats intermittent claudication & prevents stroke
• Suitable for oral tablet formulations

Applications

• Intermittent claudication tablets
• Secondary stroke prevention
• Peripheral arterial disease therapy
• Cardiovascular drug manufacturing

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings